|Partial Close, 3/2010 ||$13.5M|
|Series C, 7/2013 |
Edmond de Rothschild Venture Capital
|Series C, 4/2014 |
Edmond de Rothschild Investment Partners
Valiance Asset Management
JenaValve’s device idea was conceived by Hans-Reiner Figulla, MD, and Markus Ferrari, MD, both cardiologists at the Friedrich Schiller University Clinic, Jena, Germany. In 2006 the company was founded to develop second generation transcatheter aortic valve implantation (TAVI) systems for transapical and transfemoral implantation. At a very early state, it became clear to their research and development as well as clinical teams that safety, precision and durability are key for successful treatment, and ultimately, patient well-being.